A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease
- 14 November 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Pediatrics
- Vol. 166 (6), 565-571
- https://doi.org/10.1007/s00431-006-0280-3
Abstract
A single, 2 g/kg dose of immune globulin (IG), denoted 2 g-intravenous (IV)IG, has become a standard regimen for treating Kawasaki disease (KD) because of its highly preventive effect on coronary arterial lesions (CAL). However, IG is obtained from blood specimens, a drawback to many patients, and is also very expensive. This randomized prospective study reported here was carried out with the aim of developing a treatment regimen that would reduce the total dose of IG. The study tested two protocols (A: 2 g-IVIG; B: 1 g-IVIG) that included the strategy of administering additional IVIG to IVIG-resistant patients based on the criteria we described previously. In protocol A, an additional 2 g-IVIG was administered only once; in protocol B, the first additional IVIG was 1 g-IVIG and the second was 2 g-IVIG. One hundred and nine patients who were admitted before the seventh day of illness and had no CAL at the time of admission were enrolled in the study (protocol A: 54 patients; B: 55 patients). In the protocol A group, 7.4% (4/54) of the patients received 4 g/kg IG. In protocol B, 41.8% (23/55) were treated only with 1 g/kg IG, and 10.9% (6/55) received 4 g/kg IG. No significant differences were observed between the patients of the two subgroups receiving 4 g/kg IG in each protocol group. Discriminate analysis also suggested that 52.4% of the patients in the protocol A group could be treated only with 1 g/kg IG. On the other hand, no significant difference was observed in the incidence of aneurysms between patients in the protocol A group (1/54) and those in the protocol B group (4/55). Our protocol based on 1 g-IVIG, including additional IVIG, was assessed to be an effective treatment and to provide a considerably useful means to reduce the total dose of IG.Keywords
This publication has 14 references indexed in Scilit:
- Coronary risk factors in Kawasaki disease treated with additional gammaglobulinArchives of Disease in Childhood, 2004
- Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki diseaseEuropean Journal of Pediatrics, 2004
- Advances in Kawasaki diseaseEuropean Journal of Pediatrics, 2004
- Intravenous immunoglobulin for the treatment of Kawasaki disease in childrenCochrane Database of Systematic Reviews, 2003
- Biochemical and immunological properties of four intravenous Immunoglobulin G preparationsHuman Antibodies, 2002
- Controversies in the management of Kawasaki diseaseBest Practice & Research Clinical Rheumatology, 2002
- A Case of Intravenous Immunoglobulin-Resistant Kawasaki Disease Treated with MethotrexateYonsei Medical Journal, 2002
- Selective high dose gamma-globulin treatment in Kawasaki disease: Assessment of clinical aspects and cost effectivenessPediatrics International, 1999
- Coronary arteritis of Kawasaki disease unresponsive to high-dose intravenous gammaglobulin successfully treated with plasmapheresis.Japanese Journal of Clinical Immunology, 1995
- Risks and benefits of intravenous immunoglobulin treatment in childrenThe Journal of Pediatrics, 1995